Printer Friendly

Osteoporosis.

Foreword

Americans continue to demand a greater role in deciding issues that affect their health. Increased health awareness and the convincing evidence linking lifestyle, risk factors, and specific diseases have accelerated our need to know.

The Clinical Center, recognizing the importance of providing information to facilitate intelligent decisions on health issues, created a unique lecture series featuring physician scientists working at the frontiers of biomedical research at the National Institutes of Health.

The Medicine for the Layman series has provided an opportunity for thousands of people to learn more about how their bodies work and what they can do to maintain or improve their health.

This publication is one of several adapted from the series. It is our sincere hope that you will find this material interesting and enlightening.

John L. Decker, M.D.

Director

Warren Grant Magnuson Clinical Center

National Institutes of Health

Osteoporosis

A major health problem, osteoporosis or "porous bone" affects an estimated 20 million Americans. This bone loss disease is most common in the elderly and in postmenopausal women. The loss of bone mass places extra stress on the thin, fragile bone structure that remains causing bones to be susceptible to fracture. Osteoporosis is estimated to cause 1.3 million bone fractures a year in people over 45 years of age. Moreover, in 1985, the national estimated cost of osteoporostic fractures was estimated to be $7 billion a year.

Osteoporosis-related fractures can occur in any of the bones, but the main fractures occur in the vertebral spinal column, the wrist, and the hip. In the spinal column, loss of bone mass starts in women during their 50s and 60s. A simple action like bending forward can be enough to cause a "crush fracture" or spinal compression fracture. These vertebral fractures cause loss of height and a humped back, or a "dowager's hump".

Wrist fractures called a "Colles fracture" also commonly occur among women with osteoporosis. Typically, the fracture occurs when a woman falls and uses her hand to break the fall; this results in a broken wrist.

Fractures of the hip are the most severe. They are associated with more death, more disability, and higher medical costs than all other osteoporotic fractures combined. Twelve to 20 percent of older people with hip fractures die within a year after the fracture. Of the survivors, only a few return to the full level of activities that they enjoyed before the hip fracture.

Risk Factors

Many Risk factors for osteoporosis have been identified. They include:

* age. The chief factor for this disease is age; thie likelihood of developing osteoporosis increases progressively as we grow older.

* being a woman. Osteoporosis is estimated to be six to eight times more common in women than in men. In early adult life, women develop less bone mass than men do. Even more critical is that for years after menopause, women lose bone mass much more rapidly because of a reduction of their rpoduction of estrogen.

* early menopause. The chances of developing osteoporosis increase during early menopause or surgical menopause (after removal of the ovaries), which causes a sudden significant drop in estrogen.

* being caucasian. White women are at higher risk than black women, and white men are at higher risk than black men. In general, blacks have 10 percent greater bone mass than whites do.

* a consistently low calcium intake.

* lack of weight-bearing exercise. The significant loss of bone mass in our astronauts who spend considerable time in the weightless environment of outer space dramatically demonstrates the importance of weight-bearing exercise.

* being underweight.

* a family history of osteoporosis.

* smoking cigarettes. The concentration of estrogen in the bloodstream is lowered by cigarette smoking.

* excessive use of cortison-like drugs, such as prednisone.

Symptoms

Osteoporosis is a silent disease. Usually, it develops for many years until the bones become so weak that a minor injury can cause the bones to fracture. Detection of bone loss with ordinary x-rays does not show up until a person has lost 30 percent of their bone density.

Several techniques for early detection of bone loss have been developed in recent years. In one technique, photon absorptiometry, a machine measures how much the rays like x-rays penetrate the bone (measuring how dense the bones are). Another very useful technique is computerized tomography (CT), which uses x-rays that yield a three dimensional image.

Bone Growth and Loss

Bone continues to grow and develop throughout childhood and adolescense. During a person's twenties, bone growth increases by 15 percent. Peak bone mass, when the bones are most dense and strong, occurs at 30 to 35 years of age. After this time bone mass gradually diminishes and the bones become less dense.

There is a great need to understand how bone grows and diminishes. By studying the cellular processes responsible for bone growth, researchers hope to discover new treatments for osteoporosis. There is much active and promising research in this area.

Treatment and Prevention

Scientists now know that a leading cause of osteoporosis in women is postmenopausal estrogen deficiency. They have discovered that estrogen not only slows bone loss but also prevents bone fractures if given when a woman's production of estrogen drops. It is important that the hormone be given during or shortly after menopause because estrogen given years later is of less value. Women who have gone through menopause, and especially those with an early or surgical menopause, should discuss the benefits and risks of estrogen replacement therapy with their physicians.

Another benefit of estrogen therapy is its positive effect on the cardiovascular system. Estrogen reduces cholesterol and the concentration of other lipids (fats) in the bloodstream associated with heart disease. For women on estrogen therapy, the risk of developing endometrial cancer increases from one per 1,000 women to about four per 1,000 women. Fortunately, endometrial cancer is easy to detect and is highly curable. In fact, the death rate from endometrial cancer is lower than the death rate for osteoporotic hip fracture.

One side effect women on estrogen replacement therapy may experience is periodic bleeding. This is because estrogen therapy causes the lining of the uterus to build up. Estrogen usually is prescribed for 20 days, then the hormone is stopped for the remaining 10 days. The lining of the uterus is shed during the days off estrogen.

Progestogen, another female hormone, given in combination with estrogen may help reduce the risk of endometrial cancer. Women in the menopausal period are encouraged to discuss estrogen or progestogen therapy with their doctors.

Calcium intake

The average American consumes about 450 to 550 milligrams of calcium a day. Experts recommend that both men and women take at least 1,000 milligrams of calcium daily. This is the amount of calcium contained in three eight-ounce glasses of milk. Other sources of calcium include yogurt, cheese, salmon, canned sardines, oysters, shrimp, dried beans, and dark green vegetables such as broccoli, turnip greens, and kale.

People who do not meet their daily requirements of calcium through their diet are encouraged to take a daily supplement of calcium such as calcium carbonate, calcium lactate, calcium gluconate, or calcium citrate. Older men and women should increase their calcium intake up to 1,200 to 1,500 milligrams a day, or about four to five glasses of milk, because calcium absorption from the digestive tract is reduced in the elderly.

Exercise

Research has shown clearly that inactivity leads to bone loss. Studies revealed that astronauts in space lost a great deal of bone from lack of exercise against gravity. A program of moderate weight-bearing exercise three to four hours a week, such as brisk walking, running, tennis or aerobic dance, is recommended. Swimming is not as valuable because it is not a weight-bearing exercise.

Experimental Treatments

Several promising treatments for osteoporosis are being investigated. Calcitonin, a new drug approved by the Food and Drug Administration in 1984, slows the breakdown of bone. Calcitonin, produced naturally in the body, is a hormone produced by the thyroid gland. The synthetic form is given by daily injection and is expensive. Recently, a less expensive nasal spray of calcitonin has been developed.

Scientists also are studying fluoride combined with calcium for osteoporosis. Still experimental, flouride is promising in that it has been shown to increase bone mass. Some people experience side effects including nausea, vomiting, diarrhea, and pain in their lower extremities. Fluoride compounds currently are available for treatment in Germany and France. However, more research is needed before this treatment can be proven to be both safe and effective.

Research Directions

This booklet has described the steps to be taken to protect the bones. Recent studies on nutrition is one new area of research. Clinicians know that by taking calcium at the right time in life there is hope of preventing bone loss. Researchers also know more about exercise as a method of preventing osteoporosis.

Until recently, there were no clues as to how the hormone, estrogen, prevented osteoporosis. Now investigators have reported the discovery of estrogen receptors on bone. New methods might be harnessed to treat osteoporosis. Through continued research, there is hope for future treatments of osteoporosis. Biographical Note

Lawrence Shulman, Ph.D., M.D. Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institutes of Health (NIH)

As Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Dr. Shulman oversees the federal government's national program for the conduct and support of biomedical research and training in arthritis, bone biology and metabolism, orthopedics, muscle biology and dermatology.

Dr. Shulman received his undergraduate degree from Harvard University, and then earned both his Ph.D. in public health and his M.D. from Yale University. He trained in internal medicine at The Johns Hopkins University and Hospital and began his research studies with work on corticosteroids under a fellowship from the Endocrine Society. After a distinguished career at Johns Hopkins as Director of the Connective Tissue Division, he joined the National Institutes of Health (NIH) in 1976, where his first responsibilities were to implement programs recommended in the arthritis plan presented to Congress that year by the National Commmission on Arthritis and Related Musculoskeletal Diseases. In 1986, he was named the first Director of the newly created NIAMS.

As internationally known rheumatologist, Dr. Shulman is especially known for his studies on such rheumatic diseases as systemic lupus erythematosus and scleroderma. A major contribution was the discovery of eosinophilic fascilitis (also called Shulman Disease) in 1974.

Dr. Shulman has led major efforts at the NIH to focus research attention on osteoporosis. These include the organizing of several major scientific conferences on the disease, a consensus development conference in 1984, and scientific workshops in 1987 and in 1990. He was also a panel member of the European Consensus Development Conference on osteoporosis in Denmark in 1988. In addition, under his leadership, the Institute has developed specialized centers of research and programs of excellence in osteoporosis.
COPYRIGHT 1989 Clinical Center Communications
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1989 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Medicine for the Layman
Publication:Pamphlet by: Clinical Center Communications
Article Type:pamphlet
Date:Apr 1, 1989
Words:1819
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |